- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03097198
Effect of Plum-blossom Needle vs. Tropicamide Eye Drops on Juvenile Myopia
March 24, 2017 updated by: Tang Lewei, Wenzhou Medical University
Effect of Plum-blossom Needle vs. Tropicamide Eye Drops on Juvenile Myopia: A Cross-over Single-blind Randomized Study
The purpose of this study is to determine whether plum-blossom needle is effective in the treatment of juvenile myopia and compare the efficacy with Tropicamide Eye Drops.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Plum-blossom needle is a historical treatment technology of Traditional Chinese Medicine, and has been applied to ophthalmic diseases, such as myopia and glaucoma, for nearly one hundred years.
Study Type
Interventional
Enrollment (Anticipated)
98
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zhejiang
-
Wenzhou, Zhejiang, China, 325027
- Recruiting
- School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University
-
Contact:
- Lewei Tang, Doctor
- Phone Number: +86 15869627364
- Email: zhizhezhiwei@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years to 20 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The result of retinoscopy is myopic refractive error, near visual acuity and other visual functions must be normal
- Distance visual acuity can be corrected to normal using negative spherical or cylindrical lenses
- Myopia diopter spherical lenses must be ≤-3.00 D which measured under cycloplegia
- Subjects must be between 8 and 20 years of age
Exclusion Criteria:
- Diopter spherical lenses be >-3.00 D , or uncorrected distance visual acuity <0.1, or pathologic myopia with eye complications
- Diopter spherical lense ≥1.50 D or cylindrical lenses ≥1.00 D, as measured under cycloplegia
- The affected eyes have other diseases which affect the determination of acupuncture efficacy
- Subjects with serious systemic diseases, such as cerebrovascular, liver, kidney, hematopoietic system, and psychiatric diseases
- Longterm use of other related drugs or treatments, which have not been terminated
- Parents or subjects refuse to participate this trial
- Participating other ongoing clinical trials
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PbN-TED
Treated with plum-blossom needle first for 10 times during 20 days, followed with a one-month wash-out period and a 10-day period with Tropicamide Eye Drops.
|
Other Names:
Instill one drop in both eyes every night before bed.
Other Names:
|
|
Experimental: TED-PbN
Treated with Tropicamide Eye Drops for 10 days first, followed with a one-month wash-out period and 10 times of plum-blossom needle treatment for 20 days.
|
Other Names:
Instill one drop in both eyes every night before bed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes of vision acuity
Time Frame: Every 30 days for 150 days
|
International Standard Visual Acuity Chart
|
Every 30 days for 150 days
|
|
Changes of cycloplegic refractive errors
Time Frame: Every 30 days for 150 days
|
Measured using subjective refraction
|
Every 30 days for 150 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes of accommodation responses
Time Frame: Every 30 days for 150 days
|
Every 30 days for 150 days
|
|
Changes of accommodation facility
Time Frame: Every 30 days for 150 days
|
Every 30 days for 150 days
|
|
Changes of ciliary body thickness
Time Frame: Every 30 days for 150 days
|
Every 30 days for 150 days
|
|
Changes of axial length
Time Frame: Every 30 days for 150 days
|
Every 30 days for 150 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Yuanbo Liang, Doctor, Clinical&Epidemiological Eye Research Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2016
Primary Completion (Anticipated)
January 1, 2018
Study Completion (Anticipated)
December 1, 2018
Study Registration Dates
First Submitted
March 20, 2017
First Submitted That Met QC Criteria
March 24, 2017
First Posted (Actual)
March 31, 2017
Study Record Updates
Last Update Posted (Actual)
March 31, 2017
Last Update Submitted That Met QC Criteria
March 24, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Refractive Errors
- Myopia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Pharmaceutical Solutions
- Mydriatics
- Ophthalmic Solutions
- Tropicamide
Other Study ID Numbers
- 2016ZB080
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
IPD Plan Description
The IPD sharing plan is undecided yet.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myopia
-
Tianjin Medical University Eye HospitalNot yet recruitingProgressive Myopia | Pediatric Myopia | Orthokeratology-related Myopia Progression
-
SightGlass Vision, Inc.RecruitingMyopia | Myopia Progression | Juvenile MyopiaUnited States
-
Shanghai Eye Disease Prevention and Treatment CenterEnrolling by invitationMyopia, Child Myopia ProgressionChina
-
Shanghai General Hospital, Shanghai Jiao Tong University...Not yet recruitingMyopia | Myopia, ProgressiveChina
-
SightGlass Vision, Inc.Recruiting
-
University of FaisalabadCompletedRefractive Errors | Myopia | Progressive MyopiaPakistan
-
Beijing Airdoc Technology Co., Ltd.Recruiting
-
Beijing Airdoc Technology Co., Ltd.The First People's Hospital of XuzhouRecruiting
-
Shanghai Eye Disease Prevention and Treatment CenterActive, not recruiting
-
Shanghai Eye Disease Prevention and Treatment CenterEnrolling by invitation
Clinical Trials on Plum-blossom Needle
-
Guang'anmen Hospital of China Academy of Chinese...Unknown
-
Stanford UniversityMarz Medical, Inc.RecruitingTissue Expansion | Implant Based Breast ReconstructionUnited States
-
Chulalongkorn UniversityCompletedPreterm Birth | Postpartum WomenThailand
-
Bio Nature HealthCitruslabsCompletedCognitive Function | Cognitive Decline | MemoryUnited States
-
Samsung Medical CenterCompletedRectal CancerKorea, Republic of
-
University of California, San FranciscoCompleted
-
Stanford UniversityCompletedBreast Carcinoma | Breast DisorderUnited States
-
Guangxi Medical UniversityCompleted
-
University of SaskatchewanCompleted
-
San Diego State UniversityFlorida State UniversityCompletedBone Diseases, Metabolic